Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

JPMorgan reinstates coverage of Informa at 'overweight'

(Sharecast News) - JPMorgan Cazenove reinstated coverage of Informa on Tuesday with an 'overweight' rating following a period of restriction. The bank, which set a price target of 1,020p, said the group has transitioned through 10 years of building a leading B2B growth platform, with management's new 2025-2028 programme, One Informa, centred on maximising the value of the portfolio.

JPM said: "With focus now on the existing Live B2B Events business and simplification of the operational infrastructure, we see the company setting up for improved earnings momentum: organic revenue accelerating to JPMe +6% (CAGR25-28E), progressive margin expansion (to 29.5% in FY28E), and reduced financial leverage, driving circa 10% adjusted EPS growth, with upside on accretion through ongoing (and higher) cash returns to shareholders."

The bank argued that in order to unlock value and drive an "overdue" re-rating of the shares there are a number of steps management could take over the next 12 to 24 months.

JPM pointed to a potential increased focus on organic versus inorganic execution, the possible disposal of Taylor & Francis, de-risking through deleveraging, and further aligning remuneration to shareholder interests.

"Paired with improving near-term operational performance, we argue for both: 1) ongoing earnings upgrades (JPMe FY26/FY27 adjusted operating profit 1%/3% ahead of consensus) and 2) a further narrowing of the valuation discount to peers," it said.

At 1605 BST, the shares were up 2% at 865p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.